Free tool
Cell therapy stocks
We cover 4 companies grouped under the Cell therapy theme. The median market value in the group is $739.95M. Across the group, the median move over the past trading day is +0.59%. Price change over the past year runs from +29.2% to +224.6% across the middle 80 percent of the group, with a median of +81.1%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| BLFS | BioLife Solutions, Inc. | $1.82B | Small cap | +45.50% | Nov 5, 2026 |
| SYNC.L | Syncona Limited | $933.97M | Small cap | +22.23% | Nov 12, 2026 |
| CABA | Cabaletta Bio, Inc. | $545.94M | Small cap | +116.67% | Nov 16, 2026 |
| 0JDK.L | Iovance Biotherapeutics, Inc. | $501.00M | Small cap | +270.87% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.